In an investor update on Monday, Arcturus Therapeutics Holdings (NASDAQ: ARCT) reported early-stage clinical trial results for its coronavirus vaccine candidate. The company also said that the Singapore Health Sciences Authority had granted approval to begin a phase 2 study of that candidate, ARCT-021.
Although the results indicate that the one-dose vaccine is effective at blocking the coronavirus, it produces fewer neutralizing antibodies than the vaccine made by Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX), and the vaccine of Moderna (NASDAQ: MRNA). Compounding that, Pfizer/BioNTech’s BNT-162b2 and Moderna’s mRNA-1273 have been approved by U.S. and European Union healthcare regulators for emergency use.
Like BNT-162b2 and mRNA-1273, Arcturus’ vaccine candidate utilizes messenger RNA to instruct the body’s cells how to combat the coronavirus.